Efficacy and Safety of Bimekizumab in Chronic Plaque Psoriasis
Research type
Research Study
Full title
A phase 3, multicentre, randomised, double-blind, placebo- and active comparator-controlled, parallel-group study to evaluate the efficacy and safety of Bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis.
IRAS ID
235146
Contact name
Sirjana Gurung
Contact email
Sponsor organisation
UCB Biopharma SPRL
Eudract number
2016-003425-42
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
128707, IND Number
Duration of Study in the UK
1 years, 9 months, 17 days
Research summary
Plaque Psoriasis is the most common form of Psoriasis, a long-term skin condition that appears as raised, red patches covered with a silvery white build-up of dead skin cells or scale. These patches or plaques most often appear on the scalp, knees, elbows and lower back. They are often itchy and painful, and they can crack and bleed.
The purpose of the study is to see if Bimekizumab, the study drug is effective for treating participants with moderate to severe plaque Psoriasis. The study is also done to see if Bimekizumab is safe and to monitor for side effects. An additional purpose is to understand participants' responses to Plaque Psoriasis treatments using an approved drug called Ustekinumab.
This is a double-blinded study, meaning neither the participant nor the study doctor will know which medication is being given. The study medication will be randomly assigned; participants will receive either Bimekizumab, Ustekinumab or placebo. After Week 16, all participants will be treated with Bimekizumab or Ustekinumab.
UCB Biopharma SPRL is the sponsor of this study which will take place worldwide. It is anticipated that approximately 560 participants will be enrolled in the study. For each participant, the study will last a maximum of 72 weeks.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
18/NW/0166
Date of REC Opinion
20 Apr 2018
REC opinion
Further Information Favourable Opinion